## CRL: Charles River Laboratories International, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.15 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($171.41)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Charles River Laboratories (CRL) Shares Skyrocket, What You Need To Know**
- Source: Markets Financial Content | 20251203T215500 | Bullish | Relevance: 100%
- Shares of Charles River Laboratories (CRL) jumped 6.1% after the company provided an encouraging business update at an investor conference, highlighting positive demand trends in its Discovery and Safety Assessment (DSA) segment. The company reported that its net book-to-bill ratio has risen each month since the start of the third fiscal quarter, leading to optimism about upward trends despite potential short-term holiday seasonality. CRL shares closed at $184.69, reflecting a 5.7% increase, and are trading near their 52-week high.

**2. Charles River Laboratories (CRL) Shares Skyrocket, What You Need To Know**
- Source: Finviz | 20251203T165500 | Bullish | Relevance: 100%
- Charles River Laboratories (CRL) shares jumped 6.1% after the company provided an encouraging business update at an investor conference, highlighting positive demand trends in its Discovery and Safety Assessment (DSA) segment. The company reported that its net book-to-bill ratio has risen each month since the start of the third fiscal quarter, leading to optimism despite potential holiday seasonality. The stock closed at $184.69, up 5.7% from the previous close, reflecting a significant market reaction to the positive news.

**3. Charles River Laboratories International Inc. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251203T163000 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. stock (CRL) rose 5.67% on Wednesday, closing at $184.67. This performance outpaced broader market gains, with the S&P 500 and Dow Jones Industrial Average also seeing positive movement. The stock's increase ended a three-day losing streak for the company.

**4. Kennedy Capital Management LLC Lowers Position in Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251205T122347 | Somewhat-Bullish | Relevance: 100%
- Kennedy Capital Management LLC significantly reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 36% in Q2, selling 30,019 shares and ending the quarter with 53,345 shares worth approximately $8.09 million. Despite this, other institutions, notably Allspring Global Investments, increased their holdings, with institutional investors now owning 98.91% of the company. Charles River Laboratories reported strong quarterly results, beating analyst estimates for both EPS and revenue, and maintains a "Moderate Buy" consensus rating with an average price target of $190.86.

**5. What Charles River Laboratories International (CRL)'s Improving Discovery and Safety Assessment Bookings Trend Means For Shareholders**
- Source: Simply Wall Street | 20251205T110847 | Somewhat-Bullish | Relevance: 100%
- Charles River Laboratories International (CRL) recently highlighted improving Discovery and Safety Assessment net book-to-bill ratios at a healthcare conference, suggesting a recovery in underlying demand. While this trend indicates improving order momentum, the company still faces risks such as cancellations and pressure on margins. Investors should consider these factors despite the projected long-term revenue and earnings growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $185 | $170 | +9% |
| 2025-11-10 | TD Cowen | $197 | $205 | -4% |
| 2025-11-06 | JP Morgan | $165 | $160 | +3% |
| 2025-11-06 | Barclays | $210 | $195 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |
| 2025-11-10 | TD Cowen | main | Buy |
| 2025-11-06 | JP Morgan | main | Neutral |
| 2025-11-06 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 4 raises (avg +8%) could attract flows.
- Momentum building: MRS_20 improving +2.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.15 indicates undervaluation relative to growth. Forward P/E 16.9x stretched relative to 7% growth. Analyst sentiment positive (4 raises, avg +8%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 1.64 |
| 52W Range | $91.86 - $204.47 |
| Short Interest | 5.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.15 |
| Forward P/E | 16.9 |
| Current P/E | 18.0 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 2.1% to 4.6% (+2.5% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 83rd percentile. MRS_5 at 1.4% confirms short-term momentum alignment. AM_20 at 7.0% shows strong absolute momentum above own 20MA. Outperforming sector by 6.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.79), confirming momentum. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.62% (CS: 84) | Strong |
| RSI_14 | 62.5 | Neutral |
| MACD Histogram | 1.79 | Bullish |
| vs SMA20 | 1.070x | Above |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 1.182x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $184.31
- **Stop Loss:** $171.41 (7.0% risk)
- **Target:** $210.11 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 38
- **Position Value:** $7,003.78
- **Portfolio %:** 7.00%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*